The Australian medical landscape is buzzing with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing impressive results in early trials for managing obesity. This https://macrobookmarks.com/story21905222/retatrutide-australia-a-emerging-prospect-for-obesity-treatment